http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Emergent BioSolutions (EBS) Signs 5-Year Agreement for Large-Scale Drug Substance Manufacturing for J&J’s (JNJ) Lead COVID-19 Vaccine Candidate
-
Unilever's 'Fair & Lovely' to get makeover after backlash
-
Subcutaneous Formulation of DARZALEX®▼(Daratumumab) Combination Resulted in Deep and Rapid Haematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Li
-
Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation
-
Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST Journal
-
German coronavirus vaccine developer CureVac denies any U.S. bid
-
Germany tries to halt U.S. interest in firm working on coronavirus vaccine
-
Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.
-
AtriCure (ATRC) Appoints Karen Prange and Daniel Florin to Board
-
AtriCure Names Two Industry Veterans to Board of Directors
-
Johnson & Johnson Vision Introduces TECNIS Toric II 1-Piece IOL as New Monofocal Option for Cataract Patients with Astigmatism; Launching Multi-Center, Post-Market Clinical Trials Across U.S.
-
Actelion Withdraws Regulatory Filings to Extend the Indication of OPSUMIT® (macitentan 10mg) in CTEPH
-
Strong tech results propel S&P 500, Nasdaq
-
Several states wary of $48 billion opioid settlement proposal
-
Actelion Pharmaceuticals Reports New OPSUMIT (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical & Functional Parameters in Patients with PAH
-
New OPSUMIT® (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical and Functional Parameters in Patients with Pulmonary Arterial Hypertension
-
Boeing, J&J, dismal China data drag Wall Street lower
-
Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
-
Johnson & Johnson (JNJ) Settles Opioid Litigation with Two Ohio Counties for $20M
-
Johnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial
-
Johnson & Johnson (JNJ) Reports Data from Pivotal Ph. 3 SPARTAN Study Shows 25% Reduction in Risk of Death in Patients with nmCRPC Treated with ERLEADA (apalutamide)
-
Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients With Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (apalutamide)
-
Johnson & Johnson (JNJ) Will Appeal 'Flawed' Opioid Judgement in Oklahoma
-
Johnson & Johnson To Appeal Flawed Opioid Judgment in Oklahoma
-
Motus GI Bolsters Commercial and Quality/Regulatory Expertise with Two Key Senior Management Additions
-
New Post-hoc Analysis Shows Adding UPTRAVI® (selexipag) Versus Placebo Improved Long-Term Clinical Outcomes Regardless of Time of Treatment Initiation, and Demonstrated an Even More Pronounced Treatm
-
Johnson & Johnson (JNJ) to Highlight Strategy for Delivering Above-Market Growth at 2019 Pharmaceutical Business Review
-
Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review
-
Johnson & Johnson Vision Announces Availability of ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY in the U.S.
-
Johnson & Johnson (JNJ) Vision's Investigational Antihistamine-Releasing Contact Lens Demonstrates Positive Phase 3 Results
-
Johnson & Johnson Vision's Investigational Antihistamine-Releasing Contact Lens Demonstrates Positive Phase 3 Results
-
Interim Analysis Showed Treatment with OPSUMIT® (macitentan) Associated with Significant Improvement in Right Ventricular (RV) Function and Pulmonary Vascular Resistance (PVR) in Patients with Pulmon
-
Johnson & Johnson Vision Announces Availability in Europe of TECNIS Eyhance IOL, a Next-Generation Monofocal Intraocular Lens for Patients with Cataracts
-
Actelion Receives Complete Response Letter from U.S. FDA for OPSUMIT® (Macitentan) Supplemental New Drug Application
-
Veracyte (VCYT) Reports Strategic Collaboration with Johnson & Johnson (JNJ) Innovation in Battle Against Lung Cancer
-
Janssen Pharmaceutical Reports New Phase 3 Data from ECLIPSE Study Demonstrating Superiority of TREMFYA (guselkumab)
-
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
-
Capillary Technologies hosts #ready18' summit in Singapore, empowering brands and businesses to get Consumer ready
-
ACUVUE OASYS with Transitions Light Intelligent Technology Named Among TIME's 'Best Inventions of 2018'
-
Are Southeast Asia's Retailers and Brands 'customer #ready'?
-
Singapore National Eye Centre, Singapore Eye Research Institute And Johnson & Johnson Vision Set Sights On Halting Global Myopia Epidemic
-
LifeScan Unveils New Name and Branding for the LifeScan Diabetes Institute
-
Two Studies Measure Performance of ACUVUE OASYS with Transitions Light Intelligent Technology Contact Lenses in Simulated Sunlight, Day and Night Driving Conditions
-
Johnson & Johnson Vision Supports Patients, Ophthalmology Community Through New Products, Data, Educational Opportunities, and Charitable Giving at the 2018 AAO Annual Meeting
-
Johnson & Johnson Vision Launches Worldwide Campaign to #SpotlightSight in Honor of World Sight Day
-
Arrowhead (ARWR) Announces $3.7 Billion License and Collaboration Agreements with Janssen (JNJ)
-
HP and Johnson & Johnson challenge creative talents at Spikes Asia to transform consumer experience with digital print
-
Janssen Biotech Announces Decision Not to Continue Collaboration with Geron Corp. (GERN) for Imetelstat
-
Janssen Elects Not to Continue Agreement with Geron for Imetelstat
-
Johnson & Johnson (JNJ) Company Janssen Pharmaceutical Reports Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression

